| Original language | Italian |
|---|---|
| Pages (from-to) | 2027-2039 |
| Number of pages | 13 |
| Journal | New England Journal of Medicine |
| Volume | 379 |
| Issue number | 21 |
| DOIs | |
| Publication status | Published - 2018 |
Cite this
Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. / Camidge, D.R.; Kim, H.R.; Ahn, M.-J.; Yang, J.C.-H.; Han, J.-Y.; Lee, J.-S.; Hochmair, M.J.; Li, J.Y.-C.; Chang, G.-C.; Lee, K.H.; Gridelli, C.; Delmonte, A.; Garcia Campelo, R.; Kim, D.-W.; Bearz, A.; Griesinger, F.; Morabito, A.; Felip, E.; Califano, R.; Ghosh, S.; Spira, A.; Gettinger, S.N.; Tiseo, M.; Gupta, N.; Haney, J.; Kerstein, D.; Popat, S.
In: New England Journal of Medicine, Vol. 379, No. 21, 2018, p. 2027-2039.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer
AU - Camidge, D.R.
AU - Kim, H.R.
AU - Ahn, M.-J.
AU - Yang, J.C.-H.
AU - Han, J.-Y.
AU - Lee, J.-S.
AU - Hochmair, M.J.
AU - Li, J.Y.-C.
AU - Chang, G.-C.
AU - Lee, K.H.
AU - Gridelli, C.
AU - Delmonte, A.
AU - Garcia Campelo, R.
AU - Kim, D.-W.
AU - Bearz, A.
AU - Griesinger, F.
AU - Morabito, A.
AU - Felip, E.
AU - Califano, R.
AU - Ghosh, S.
AU - Spira, A.
AU - Gettinger, S.N.
AU - Tiseo, M.
AU - Gupta, N.
AU - Haney, J.
AU - Kerstein, D.
AU - Popat, S.
N1 - Cited By :15 Export Date: 4 February 2019
PY - 2018
Y1 - 2018
U2 - 10.1056/NEJMoa1810171
DO - 10.1056/NEJMoa1810171
M3 - Articolo
VL - 379
SP - 2027
EP - 2039
JO - New England Journal of Medicine
JF - New England Journal of Medicine
SN - 0028-4793
IS - 21
ER -